Home » IPU partners with Sport Ireland on Medcheck as WADA 2026 Prohibited List published
The IPU National Health Products Catalogue has partnered with Sport Ireland to support the ongoing development and maintenance of Medcheck, a vital online resource that allows athletes, healthcare professionals, and the general public to verify whether their medications contain substances banned under the World Anti-Doping Agency (WADA) guidelines.
Medcheck, accessible via medcheck.sportireland.ie, is designed to help people in Ireland make informed decisions about over-the-counter and prescription drugs, ensuring compliance with anti-doping regulations. With the IPU NHPC now contributing to the regular updating and accuracy of the database, this collaboration strengthens the integrity of Irish sport, enhances athlete education around medication safety, and promotes the Sport Ireland message of Clean Sport.
As athletes and support personnel prepare for next year, it’s crucial to understand the latest updates to the 2026 WADA Prohibited List, which come into effect on 1 January.
In addition to the 2026 WADA Prohibited List, two supplementary documents were also published — The 2026 Summary of Major Modifications and Explanatory Notes and The 2026 Monitoring Program, which includes substances that are not on the List, but that WADA wishes to monitor in order to detect potential patterns of misuse in sport (both documents and the Prohibited List are available at wada-ama.org > Resources > Prohibited List).
Below is a summary of the key modifications and clarifications. Please consult the above listed documents for full guidance and information.
It was clarified that withdrawal of blood or blood components is prohibited except for
Note that Platelet-Rich Plasma (PRP) and related procedures remain not prohibited.
The non-diagnostic use of carbon monoxide was added to the Prohibited Methods as a new section, M 1.4. Carbon monoxide can increase erythropoiesis under certain conditions. The use of carbon monoxide for diagnostic purposes, is not prohibited.
Cell components (for example, nuclei and organelles such as mitochondria and ribosomes) are added to the existing prohibition of using normal or genetically modified cells.
There have been two new additions to the S6.A list of non-specified substances. These unapproved substances are potent analogs of modafinil and adrafinil and are sold as supplements.
It has been clarified in the ‘Glucocorticoids Washout Table’ that use of sustained-release formulations may result in detectable glucocorticoid levels past the washout period due to prolonged systemic absorption. ‘Depo’ injections are commonly used sustained release formulations (more information can be found in Glucocorticoids and Therapeutic Use Exemptions, available at wada-ama.org > Resources > Therapeutic Use Exemption > Glucocorticoids and Therapeutic Use Exemptions).
WADA has updated the Monitoring Programme for 2026. It is clarified that the urine monitoring of semaglutide includes also the monitoring of tirzepatide.
Tramadol and fentanyl will continue to be monitored for their use by athletes in the out-of-competition period.
Use resources such as the WADA Prohibited List and verify the status of medications by using MedCheck
If it has been identified that supplements are required, to minimise the risk of supplement contamination, only use supplements which have been batch-tested via Informed Sport (see sport.wetestyoutrust.com). Check out the Supplements and Herbal Remedies page on the Sport Ireland Anti-Doping website for more information (go to sportireland.ie > Our Work > Anti-Doping > Athlete Zone > Supplements and herbal remedies).
Consult medical professionals or anti-doping officers if unsure about a substance or method.
FAQ
Frequently asked questions regarding the Prohibited List can be found at wada-ama.org > Resources > Prohibited List, and by scrolling to the end of the page.
Noelle Horan
Medicines Information Pharmacist, IPU
Highlighted Articles